Documents show profit-seeking behind price hikes at Turing, Valeant

By Sarah N. Lynch and Caroline Humer WASHINGTON/NEW YORK (Reuters) - A decision by Turing Pharmaceuticals to increase profits by raising the price of a lifesaving drug by 5,000 percent drove some patient co-pays up to $16,000, according to excerpts of documents that congressional committee members made public on Tuesday. The excerpts, which are highlighted in memos released by Democrats on the powerful U.S. House of Representatives Committee in Oversight and Government Reform, give a rare behind